Moxibustion for hypertension: a systematic review by Kim, Jong-In et al.
Kim et al. BMC Cardiovascular Disorders 2010, 10:33
http://www.biomedcentral.com/1471-2261/10/33
Open Access RESEARCH ARTICLE
© 2010 Kim et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article Moxibustion for hypertension: a systematic review
Jong-In Kim†1, Jun-Yong Choi†2, Hyangsook Lee3, Myeong Soo Lee*4,5 and Edzard Ernst5
Abstract
Background: Moxibustion is a traditional East Asian medical therapy that uses the heat generated by burning herbal 
preparations containing Artemisia vulgaris to stimulate acupuncture points. The aim of this review was to evaluate 
previously published clinical evidence for the use of moxibustion as a treatment for hypertension.
Methods: We searched 15 databases without language restrictions from their respective dates of inception until 
March 2010. We included randomized controlled trials (RCTs) comparing moxibustion to either antihypertensive drugs 
or no treatment. The risk of bias was assessed for each RCT.
Results: During the course of our search, we identified 519 relevant articles. A total of 4 RCTs met all the inclusion 
criteria, two of which failed to report favorable effects of moxibustion on blood pressure (BP) compared to the control 
(antihypertensive drug treatment alone). However, a third RCT showed significant effects of moxibustion as an adjunct 
treatment to antihypertensive drug therapy for lowering BP compared to antihypertensive drug therapy alone. The 
fourth RCT included in this review addressed the immediate BP-lowering effects of moxibustion compared to no 
treatment. None of the included RCTs reported the sequence generation, allocation concealment and evaluator 
blinding.
Conclusion: There is insufficient evidence to suggest that moxibustion is an effective treatment for hypertension. 
Rigorously designed trials are warranted to answer the many remaining questions.
Background
By 2025, the number of adults with hypertension is pre-
dicted to be 1.56 billion worldwide [1]. Despite the efforts
of conventional healthcare, more than 50% of the patients
with high blood pressure (BP) fail to satisfactorily control
this condition [2]. One reason is the adverse effects of
many antihypertensive drugs, which result in patient
noncompliance [3]. Therefore, a substantial proportion of
hypertensive patients resort to complementary and alter-
native medicines to reduce their BP [4,5].
Moxibustion is a traditional East Asian medical inter-
vention that involves the burning of moxa (i.e., Artemisia
vulgaris  o r  m u gw o rt )  d i r ect l y  o r  i n d i r ec t l y  a t  t h e  a cu -
puncture points. The indications of moxibustion include
breech presentation, dysmenorrhea, knee osteoarthritis,
diarrhea, asthma, stroke, cancer and hypertension, and so
on [6,7]. Unlike the acupuncture stimulation, which
involves thrusting or twisting needles, resulting in vari-
ous biochemical reactions that can have effects through-
out the body, moxibustion uses heat stimulation at
various temperature levels from mild skin warming to tis-
sue damage from burning. This heat stimulation can yield
inflammatory responses and induce vascular changes. It
is suggested that around the sites of moxibustion therapy,
mediators such as histamine and substance P are released
and induce vasodilatation in mice [8]. Such inflammatory
responses that affect vascular activity might have some
potential to alleviate various cardiovascular diseases,
including hypertension. Several animal studies have dem-
onstrated effects on BP following moxibustion treatment.
For example, moxibustion given at the acupuncture point
of GV26 during halothane anesthesia in non-hyperten-
s i v e  d o gs  r e s u l t ed  i n  a n  i n cr eas e  i n  a rt e ri a l  B P  wi t h  a
decrease in peripheral resistance [9]. In hypertensive rats,
moxibustion given at BL15 decreased the systolic BP
(SBP) [10]. Because no review of moxibustion for hyper-
tension is currently available, we conducted a systematic
review to evaluate the effectiveness of moxibustion as a
treatment for hypertension in human patients.
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Methods
Data sources
We performed literature searches in the following elec-
tronic databases from their respective dates of inception
until March 2010: MEDLINE, EMBASE, CINHAL,
PsycInfo, The Cochrane Library 2010 (Issue 2), 6 Korean
medical databases (Korean Studies Information, DBPIA,
Korea Institute of Science and Technology Information,
Korea Education and Research Information Service,
KoreaMed and Korean National Assembly Library), the
Chinese Medical Database (CNKI) and three Japanese
medical databases (Japan Science and Technology Infor-
mation Aggregator, Electronic Science Links Japan, Cita-
tion Information by National Institute of Informatics).
The search terms used were "moxibustion" and ("blood
pressure" or "hypertension") in Korean or Chinese or
English. We also manually searched files from our depart-
ment and several relevant journals (The Journal of
Korean Oriental Medicine, The Journal of Korean Acu-
puncture and Moxibustion Society, The Korean Journal
of Meridian and Acupoint, Journal of Korean Oriental
Internal Medicine, Journal of Japan Society of Acupunc-
ture and Moxibustion, Focus on Alternative and Comple-
mentary Therapies, Forschende Komplementärmedizin
und Klassische Naturheilkunde) (Research in Comple-
mentary Medicine and Classical Natural Medicine) until
March 2010. References were addressed in all the original
articles, and reviews were further searched for relevant
studies. Dissertations and abstracts during this period
were also included.
Study selection
The inclusion criteria for our review were randomized
controlled trials (RCTs) in which moxibustion was
administered to human participants with arterial hyper-
tension, which was defined as SBP of 140 mmHg or
higher and/or diastolic BP (DBP) of 90 mmHg or higher.
All included studies should use an antihypertensive drug
or no treatment as a control. Cases where moxibustion
was combined with other therapies were excluded from
the review. However, subjects taking antihypertensive
drugs in combination with moxibustion were included.
Studies using interventions of unproven efficacy (e.g.,
herbs) in the control group were also excluded.
Extraction of data and quality assessment
All the included articles were read in full. Two indepen-
dent reviewers (JIK and JYC) extracted the data accord-
ing to predetermined criteria (Table 1). The Cochrane
classification (i.e., randomization, blinding, withdrawals
and allocation concealment) was applied to evaluate the
risk of bias [11]. In moxibustion trials, practitioner blind-
ing is impossible, and the blinding of the assessors and
participants was assessed separately. We defined assessor
blinding as an independent person who did not know the
participants' allocation who then performed the evalua-
tion of the outcome measures. Differences of opinions
between the reviewers were settled through discussion.
Data synthesis
The mean difference and 95% confidence intervals (CIs)
was calculated using the same software for continuous
data, and relative risk with 95% CIs was used for dichoto-
mous data in each outcome measure using the Cochrane
Collaboration's software (Review Manager version 5.0 for
Windows, Copenhagen: The Nordic Cochrane Centre).
Results
Study description
We identified 519 articles, of which 515 were excluded
(Fig 1). Nine RCTs were among the excluded articles for
the following reasons: 5 of the RCTs were excluded
because moxibustion was co-administered with other
treatments of unproven efficacy [12-16], two RCTs
included acupuncture as the control treatment [17,18],
one was a duplicate article [19] and the last was an RCT
of moxibustion on pre-hypertension subjects [20]. The
key data from the 4 RCTs that met our inclusion criteria
are listed in Table 1[21-24]. Of these included studies,
three were conducted in China [21-23] and one in Korea
[24]. All of the included trials had parallel group designs
with two groups. Three RCTs [21,23,24] used direct mox-
ibustion, and one [22] employed indirect moxibustion
treatment. The main outcome measures were the
response rate in two RCTs [21,22], and the SBP or DBP in
two RCTs [23,24].
Risk of bias assessment
N o n e  o f  t h e  i n c l u d e d  R C T s  r e p o r t e d  a n y  m e t h o d s  o f
sequence generation or allocation concealment. One trial
mentioned drop-outs and withdrawals [24]. All of the
included RCTs failed to report evaluator blinding.
Details of included trials
Jin et al. [21] conducted an RCT to assess the effects of
moxibustion on hypertensive patients. Patients were
divided randomly into two parallel groups: moxibustion
(30 min once daily for 10 days, n = 30) and antihyperten-
sive drugs only (n = 30). The outcome measures included
the response rate of the reduction in BP and hypertensive
symptoms including headache, dizziness, and insomnia.
The response rate of the reduction in BP was defined as
the percentage of responders whose DBP decreased more
than 10 mmHg or whose SBP decreased more than 30
mmHg. The response rate of the reduction in hyperten-
sive symptoms was defined as the percentage of respond-
ers whose hypertensive symptoms in the context of the
TCM diagnosis, i.e., headache, dizziness and irritation,
decreased from the baseline levels. At the end of the trial,
83% of the patients from the experimental group had aK
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Table 1: Summary of the randomized clinical studies of moxibustion for hypertension
First author 
(year)
Mean age or ranges 
(years)
Sex (M/F)
Duration of disease 
(years)
Intervention (regimen) Control (regimen) Main outcomes Intergroup difference Treated acupuncture 
points
Jin
(2008)
[21]
Moxa: 46.5
(19/11); 5.3
Cont: 47.4
(16/14); 6.2
Moxa (30 min, once daily for 10 
days, n = 30)
Direct (a multifunctional apparatus 
for moxibustion without smoke),
non-suppurative
Antihypertensive drugs 
(enalapril 10 mg 1 T qd for 10 
days, n = 30)
1) Response rate (BP)
2) Response rate 
(Symptoms: headache, 
dizziness and insomnia)
1) NS,
RR, 1.04 [0.82, 1.32]
2) NS,
RR, 1.20 [0.88, 1.64]
GV20, PC6, CV4, ST36, KI1
Zhang
(2007)
[22]
Moxa: 18-72 (16/14); 2-8
Cont: 35-69 (11/10); 2-16
Moxa (2 hr, 2 times weekly for 1 
month, total 10 times, n = 30)
Indirect,
non-suppurative
Antihypertensive drugs 
(Various doses of amlodipine 
from 2.5 mg to 10 mg, qd for 
1 month, n = 30)
1) Response rate (BP)
2) Response rate 
(Symptoms: headache, 
dizziness and insomnia)
(1) NS,
RR, 0.86 [0.63, 1.18]
(2) NS,
RR, 1.26 [0.94, 1.69]
CV8
Deng
(2002)
[23]
Moxa: 58.3
(16/14); n.r.
Cont: 58.3
(13/17); n.r.
Moxa (n.r. once, n = 30), plus (B)
Direct, suppurative
Antihypertensive drugs 
(Nifedipine sustained release 
tablet 10 mg bid for 50 days)
1) SBP
2) DBP
1) P < 0.001 (after 30 min)
MD, 13.65 [11.54, 15.76];
P < 0.001 (at 50 days)
MD, 17.4 [14.14, 20.66]
2) P < 0.001(after 30 min)
MD, 8.7 [7.07, 9.28]
P < 0.001 (at 50 days)
MD, 13.12 [14.14, 20.66]
GB39, ST36
Kim
(2005)
[24]
Moxa: 61.5
(9/21); n.r.
Cont: 66.1
(11/20); n.r.
Moxa (5 times for 2 hours, once, n = 
30)
Direct, non-suppurative
No treatment (n = 31) 1) SBP
2) DBP
1) NS (after 30 min)
MD, -1.67[-5.91, 2.57]
P < 0.001(after 60 min)
MD, 5.28 [1.14, 9.42]
P < 0.001 (after 90 min)
MD, 9.35 [5.12, 13.58]
P < 0.001 (after 120 min)
MD, 10.75 [6.48, 15.02]
2) NS (after 30 min)
MD, -0.62 [-2.63, 1.39]
NS (after 60 min)
MD, 1.06 [-1.13, 3.25]
NS (after 90 min)
MD, 1.04 [-1.24, 3.32]
NS (after 120 min)
MD, 2.44 [-0.19, 5.07]
ST36 (Men, left; women, 
right)
Moxa: moxibustion; nr: not reported; BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure; RR: risk ratio; MD: weighted mean difference; NS: no significant differenceKim et al. BMC Cardiovascular Disorders 2010, 10:33
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reduced BP, and 80% had improved hypertensive symp-
toms. The corresponding rates for the control group were
80% and 67%, respectively. There were no significant dif-
ferences between the two groups in either outcome mea-
sure.
Zhang et al. [22] tested the effects of indirect moxibus-
tion on the BP and hypertensive symptoms. Sixty patients
were randomized into two groups, those receiving moxi-
bustion (2 hr, 2 times weekly for 1 month, n = 30) or anti-
hypertensive drug alone (n = 21). The definition of the
response rates in the BP and symptoms were the same as
in the Jin et al. study [21]. The response rate of the BP was
70% for the moxibustion group (81% for control) and 90%
for the improvement of hypertensive symptoms (control:
71%). These parameters failed to yield significant inter-
group differences.
Deng et al. [23] carried out an RCT to assess the acute
antihypertensive effects of moxibustion and the effective-
ness of combined moxibustion and antihypertensive drug
therapy on SBP and DBP compared to antihypertensive
drug therapy alone in 60 hypertensive patients. After the
baseline BP measurement, moxibustion was performed
once in 30 patients with intentional burn suppuration,
while no treatment was administered to the 30 control
patients. The BP was assessed again after 30 min. After
this, antihypertensive drugs were administered to all 60
patients for 50 days, and the BP was followed up without
any further moxibustion treatment. Moxibustion reduced
the SBP and DBP significantly after 30 min of treatment
(acute effects), and moxibustion combined with drug
therapy reduced the SBP and DBP significantly after 50
days of intervention compared to drug therapy only.
A study performed by Kim et al. [24] consisted of an
RCT evaluating the immediate hypertensive effect of
moxibustion compared to no treatment. Sixty-one hyper-
tensive patients were randomized into two groups: one
treatment of moxibustion (n = 30) or no treatment (n =
31). The primary outcome was a change in BP at 30, 60,
90 and 120 minutes following treatment. The SBP was
significantly reduced in the moxibustion group compared
to the control patients at 60, 90 and 120 min after treat-
ment.
We did not perform meta-analysis to avoid the possible
bias from pooling of studies with low methodological
quality.
Discussion
By our assessment, the appropriate randomization, allo-
cation concealment and assessor blinding were not
reported in any of the 4 RCT s included in our review .
Only one study [24] reported the withdrawals and drop-
outs. This suggests that the risk of bias was high in each
of the included studies, potentially leading to false posi-
tives. Moreover, all of the studies originated from China
and Korea in East Asia. Therefore, additional indepen-
dent studies in different countries are desirable to deter-
mine the generalizability of the results.
In this review, different moxibustion techniques were
used in the included RCTs. It is reported that there are
more than 50 techniques of moxibustion therapy, and
these can be largely classified into direct moxibustion,
indirect moxibustion and moxibustion with a moxa stick.
Each technique has its own purpose for given situations
[25].
Traditionally, direct moxibustion is the main therapy
intended to warm and heat the local area by burning a
moxa cone. This technique can be applied into two ways,
the suppurative (scarring) and non-suppurative (non-
scarring) methods. Suppurative moxibustion leaves a
burn scar and can yield a very strong inflammatory
response, whereas non-suppurative moxibustion is a
technique of milder heat stimulation at the local site
without any blisters. In the present review, the RCTs of
Jin et al., Deng et al., and Kim et al. [21,23,24] adminis-
tered direct moxibustion therapy, and only the Deng et al.
trial [23] employed suppurative moxibustion and showed
significant efficacy in both the SBP and DBP at 30 min
and 50 days after the moxibustion therapy.
In indirect moxibustion therapy, a layer of various
herbal medicines, such as ginger, garlic, salt and others, is
placed between the moxa cone and skin. The purpose of
this technique is the absorption of the therapeutically
active components of the herbal medicines into the skin
in various conditions combined with heat stimulation by
moxibustion. Zhang et al. [22] administered indirect
moxibustion therapy using mixed powders of various
herbal medicines, including Astragalus membranaceus,
Figure 1 Flowchart of the trial selection process. RCT: randomized 
clinical trial.Kim et al. BMC Cardiovascular Disorders 2010, 10:33
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Panax notoginseng, Schisandra chinensis and musk in an
umbilicus, without any statistically significant efficacy.
We found no RCTs using moxibustion with a moxa
stick in which the moxa stick is placed 2-3 cm from the
skin with the intention of mildly warming local sites.
For the optimal moxibustion therapies in future hyper-
tension trials, studies regarding the appropriate moxibus-
tion techniques (direct vs. indirect or other techniques)
and the appropriate selection of the herbal cake for indi-
rect moxibustion should be performed. Meanwhile, other
techniques should be considered as possible moxibustion
therapies for hypertension.
Acupoints are another issue in our review. All of the
included RCTs except Zhang et al. used ST36. This point
showed anti-hypertensive effects in experimental studies
when stimulated by acupuncture or electroacupuncture
[26,27]. However, all of the included RCTs in our review
did not employ any acupoints that had been shown to be
antihypertensive by moxibustion stimulation [9,10].
Of the 4 RCTs included here, two studies [21,22]
reported response rates by the categorization of the BP
change as the primary outcome. This parameter cannot
provide the extent of BP reduction or the precise magni-
tude of effect. Although moxibustion showed non-signifi-
cant differences from antihypertensive drug treatment
with respect to the response rate, we cannot conclude
that the BP effect of moxibustion is comparable to that of
antihypertensive drugs. This categorical reporting
method is common in traditional Chinese medicine
research [28]. Thus, additional information on the BP is
required to interpret such data.
Two RCTs evaluated the acute effects of moxibustion
on BP [23,24]. Of these, one RCT [23] reported a statisti-
cally significant BP decrease at 30 minutes after suppura-
tive moxibustion compared to no treatment, while the
other study of non-suppurative moxibustion [24] failed to
show a significant BP decrease at 30 minutes but showed
a significant BP decrease only after 60 minutes. Further-
more, this trial of non-suppurative moxibustion therapy
has the limitation of not estimating the long-term effects
on BP [24]. The suppurative moxibustion RCT [23] that
showed an acute antihypertensive effect also showed sig-
nificant differences at 50 days after a single treatment, but
uncertainty about the effectiveness of a single moxibus-
tion still remains. Also, this RCT [23] showed the superi-
ority of the moxibustion plus antihypertensive drug
therapy compared to the antihypertensive drug therapy
alone. However, due to the design (A+B versus B), this
RCT is unable to demonstrate the specific therapeutic
effects of the tested treatment [29]. Two RCTs failed to
generate positive effects for moxibustion on BP com-
pared to antihypertensive drug therapy [21,22]. Whether
the findings of no difference compared to drug therapy
reflect an equivalence of effects is unclear. All of these
RCTs have small sample sizes, leading to a higher proba-
bility of a type II error. Also, the number of trials and the
methodological quality are too low to draw firm conclu-
sions.
All of the RCTs included in our review failed to blind
patients because the regimen in the control group (i.e.,
antihypertensive drugs or no treatment) was easily distin-
guishable from moxibustion therapy. This suggests that
the control groups in these RCTs were inappropriate to
determine any specific effect of moxibustion. Recently, a
sham device for moxibustion has been developed, making
patient-blinding in sham-controlled trials possible [30].
None of the included RCTs reported on adverse events.
Furthermore, one RCT, in which intentional suppurative
moxibustion therapy was used, had no record of the prog-
ress of suppuration and burning in moxibustion-treated
participants [23]. Burning has been reported in moxibus-
tion therapy [31], and any minor burning must be moni-
tored. In addition, adverse effects due to smoke can occur
during moxibustion and should be monitored with cau-
tion [32].
One of the merits of our review is the extensive search
strategy without language restriction. However, there is
always the possibility of missing studies, not in the least
because of a negative publication bias [33-35].
Conclusion
There are currently only a few trials of moxibustion for
the management of hypertension that have been pub-
lished. Collectively, the existing evidence does not sug-
gest that moxibustion is an effective therapy for this
indication. Future studies should be of high quality with
particular emphasis on using adequate control interven-
tions and differentiating between specific and non-spe-
cific effects.
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